Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study

Simple item page
dc.contributor.authorHompe, Eliza D.
dc.contributor.authorJacobson, Denise L.
dc.contributor.authorEudailey, Joshua A.
dc.contributor.authorButler, Kevin
dc.contributor.authorEdwards, Whitney
dc.contributor.authorPollara, Justin
dc.contributor.authorBrummel, Sean S.
dc.contributor.authorFouda, Genevieve G.
dc.contributor.authorChinula, Lameck
dc.contributor.authorKamanga, Melvin
dc.contributor.authorKinikar, Aarti
dc.contributor.authorMoodley, Dhayendre
dc.contributor.authorOwor, Maxensia
dc.contributor.authorFowler, Mary Glenn
dc.contributor.authorPermar, Sallie R.
dc.date.accessioned2022-03-08T10:28:52Z
dc.date.available2022-03-08T10:28:52Z
dc.date.issued2019
dc.description.abstractTo design immune interventions that can synergize with antiretroviral therapy (ART) to reduce the rate of HIV mother-to-child transmission (MTCT), it is essential to characterize maternal immune responses in the setting of ART during pregnancy and breastfeeding and define their effect on MTCT. Prior studies reported an association between breast milk envelope (Env)-specific antibodies and antibodydependent cell cytotoxicity (ADCC) activity with reduced postnatal transmission. In this study, we investigated whether these immune correlates were similarly associated with protection in a matched case-control study of mother-infant pairs receiving maternal ART or infant nevirapine prophylaxis during breastfeeding in the International Maternal-Pediatric-Adolescent AIDS Clinical Trials Network Promoting Maternal-Infant Survival Everywhere (PROMISE) trial, assessing postnatal transmission risk in 19 transmitting and 57 nontransmitting mothers using conditional logistic regression models adjusted for maternal plasma viral load. The odds ratios of postnatal MTCT for a 1-unit increase in an immune correlate were 3.61 (95% confidence interval [CI], 0.56, 23.14) for breast milk Env-specific secretory IgA (sIgA), 2.32 (95% CI, 0.43, 12.56) for breast milk and 2.16 (95% CI, 0.51, 9.14) for plasma Env-specific IgA, and 4.57 (95% CI, 0.68, 30.48) for breast milk and 0.96 (95% CI, 0.25, 3.67) for plasma ADCC activity, with all CIs spanning 1.0. Interestingly, although mucosal IgA responses are poor in untreated HIV-infected women, there was a strong correlation between the magnitudes of breast milk and plasma Env-specific IgA in this cohort. In this analysis of the small number of postnatal virus transmissions in the landmark PROMISE study, no single antibody response was associated with breast milk transmission risk.en_US
dc.identifier.citationHompe ED, Jacobson DL, Eudailey JA, Butler K, Edwards W, Pollara J, Brummel SS, Fouda GG, Chinula L, Kamanga M, Kinikar A, Moodley D, Owor M, Fowler MG, Permar SR. 2019. Maternal humoral immune responses do not predict postnatal HIV-1 transmission risk in antiretroviral-treated mothers from the IMPAACT PROMISE study. mSphere 4:e00716-19. https://doi.org/10.1128/mSphere .00716-19.en_US
dc.identifier.urihttps://doi.org/10.1128/mSphere .00716-19.
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/2551
dc.language.isoenen_US
dc.publisherMsphereen_US
dc.subjectADCCen_US
dc.subjectHIV-1en_US
dc.subjectAntibodiesen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectBreast milken_US
dc.subjectPostnatal transmissionen_US
dc.titleMaternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Maternal Humoral Immune Responses Do Not Predict.pdf
Size:
641.91 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences